8-K current report · filed Jul 16, 2026

Insmed Incorporated (INSM) 8-K Current Report: July 16, 2026

Item 7.01Item EX-99.1Item EX-99.2INSM overview

Short answer

Insmed Incorporated (INSM) filed an 8-K current report with the SEC on July 16, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Insmed announced 12-month safety and efficacy data for treprostinil palmitil inhalation powder in pulmonary arterial hypertension.

Insmed Incorporated 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Insmed announced 12-month safety and efficacy data for treprostinil palmitil inhalation powder in pulmonary arterial hypertension
  • Data come from an ongoing open-label extension study, informing durability and longer-term tolerability
  • Conference call and investor presentation scheduled for July 16, 2026, at 8:00 a.m. Eastern Time

Item EX-99.1 · Exhibit EX-99.1

  • TPIP delivered sustained 12-month efficacy improvements, supporting advancement of the once-daily therapy into Phase 3 PALM-PAH
  • 6MWD improved 55.7 meters in TPIP Continued and 54.1 meters in Placebo Crossed groups
  • NT-proBNP declined approximately 60%, while 78.3% and 80.6% achieved WHO Functional Class I or II
  • Approximately 65% achieved Refined Low Risk status, associated with less than 5% estimated three-year mortality risk
  • No newly identified safety signals through doses up to 1,280 µg; four deaths occurred, none considered TPIP-related

Item EX-99.2 · Exhibit EX-99.2

  • 12-month open-label extension supports sustained TPIP efficacy in PAH, with 6MWD gains of 55.7 meters for continued treatment and 54.1 meters after placebo crossover
  • NT-proBNP declined approximately 60% in both groups by Month 6 and remained reduced at Month 12
  • Approximately 80% achieved WHO Functional Class I or II, while approximately 65% reached refined low-risk REVEAL status
  • 91% of 91 OLE patients remained on TPIP at Month 12, supporting once-daily adherence and tolerability
  • Safety remained a key watchpoint: 4.4% deaths, 18.7% serious TEAEs, and 7.7% discontinuations, though none were considered drug-related മരണ

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Insmed Incorporated 8-K filings

Get the next INSM 8-K as it lands

Follow INSM for push alerts, or ask the research agent what this filing means.